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The fifth Expedition Inspiration conference was held
on March 1–3, 2001. While there are other confer-
ences that concentrate on a particular facet of breast
cancer, the design and goals of this conference are
unusual. In order to maximize interaction of invest-
igators and clinicians the meetings are small, invited,
and private. The participants include both senior and
junior physicians and scientists involved in clinical
and basic research as well as clinical practice. The
meetings serve four purposes:
1. Active discussion among participants who do not
usually interact.
2. Develop consensus as to the state of our knowledge
as well as an action plan to stimulate future studies.
3. Develop collaborative projects among the meeting
participants.
4. Foster new investigations by participants as well as
others.
This year the role of hormones in the etiology,
prognosis, prevention and treatment of breast cancer
were the subject of the discussion. Investigators study-
ing breast cancer biology, endocrinology, molecular
biology, epidemiology and clinical management par-
ticipated in a stimulating discussion resulting in the
consensus and action items which follow:
Selective estrogen receptor modulators (SERMs),
aromatase inhibitors, and ovarian ablation
A number of new hormonal agents are becoming avail-
able for the treatment of breast cancer. These include
pure antiestrogens, such as faslodex, new SERMs that
appear not to increase the risk of endometrial can-
cer, such as raloxifene, and aromatase inhibitors. At
least two aromatase inhibitors have shown efficacy
equal to or greater than that of tamoxifen in the treat-
ment of postmenopausal women with receptor positive
metastatic breast cancer.
One challenge is to determine whether incorporat-
ing the new hormonal agents into adjuvant regimens
can improve long term disease free survival. Several
trials using aromatase inhibitors in the adjuvant ther-
apy of postmenopausal women are ongoing or have
completed accrual.
Young women (under the age of 35) with re-
ceptor positive tumors who are treated with CMF-type
chemotherapy and do not receive endocrine therapy
have been reported to have a worse prognosis than
older premenopausal patients with receptor positive
tumors as well as a worse prognosis than equally
young women with receptor negative tumors. These
very young women are those who are least likely to
undergo menopause as a result of chemotherapy, and it
may be that continued hormonal stimulation of tumor
cells contributes to their poor prognosis.
Numerous trials have shown that ovarian ablation
produces results similar to those produced by chemo-
therapy in premenopausal women with receptor posit-
ive tumors. A large part of the benefit of chemotherapy
in young women may be the result of chemotherapy-
induced menopause. One important question is the
value of chemotherapy when added to optimal hor-
monal therapy in premenopausal women. Including
quantitation of levels of ER and PR positivity in such
trials might allow for estimation of differential benefit
in patient subgroups.
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A second question is the nature of the optimal hor-
monal regimen. Ovarian ablation and tamoxifen have
been found to produce similar results in the setting
of advanced disease. Recent results in premenopausal
women with receptor positive metastatic breast cancer
have suggested that the combination of tamoxifen plus
ovarian ablation (via GnRH agonist) may produce a
survival advantage over the use of either agent alone.
Aromatase inhibitors cannot be used in premenopausal
women except in the setting of ovarian ablation, and
should they prove superior to tamoxifen in postmeno-
pausal women, their use in younger women will need
to be addressed. Young women have more side effects
from hormonal therapy than do older women, includ-
ing infertility, osteoporosis, vasomotor symptoms, and
urogenital atrophy. Clinical trials addressing hormonal
therapy need to include careful assessment of relevant
toxicities.
Action Items. Clinical trials of hormonal therapy in
receptor positive premenopausal women are needed.
Questions to be addressed include the optimal agents,
duration of therapy, and importance of chemotherapy
in the setting of optimal hormonal treatment. Such
trials should report both ER and PR status. Careful
assessment of relevant toxicities is crucial.
Clinically relevant subsets of ER-positive breast
tumors
Overexpression of the estrogen receptor (ER, alpha
isoform) has long been recognized as a breast can-
cer prognostic marker and even a stronger predictive
marker of response to endocrine therapy. Three emer-
ging lines of evidence now support the likelihood that
ER-positive breast tumors can be divided into at least
two clinically relevant subsets, one with good respons-
iveness to endocrine therapy and relapse-free patient
survival, and the other with much poorer endocrine
responsiveness and patient outcome.
1. The independent prognostic value of ER-
positivity has formerly been shown to be time-depen-
dent; that is, associated with better patient prognosis
(relapse-free survival) than ER-negativity especially
within the first 5 years after primary tumor dia-
gnosis and excision. However, when stage-matched
and untreated ER-positive primary tumors are care-
fully followed-up over much longer time intervals, two
distinct prognostic subsets emerge based on patient
menopausal status. For postmenopausal women, ER-
positive and ER-negative breast tumors appear to be
associated with comparable longterm patient survival.
In contrast, ER-positive breast tumors in premeno-
pausal patients not treated with adjuvant therapy are
associated with a significantly worse patient survival
than comparably staged and untreated ER-negative
tumors.
Action item. Further study of archived ER-positive
tumors from early-staged premenopausal patients not
treated with adjuvant therapy to validate this pro-
vocative observation; and multivariate analysis of
other established breast tumor prognostic markers
(e.g., PR, S-phase, ErbB2, p53) in stage-matched
ER-positive tumors from premenopausal versus post-
menopausal patients that might explain the prognostic
differences of ER-positivity based on menstrual
status.
2. RNA samples from a small group of primary
T3 and T4 breast tumors from patients with long
term follow-up, analyzed by expression microarrays
(9,000 cDNA clones per array) and clustering pro-
grams, identified two ER-positive tumor subsets hav-
ing luminal gene expression characteristics (Types A
and B). Survival analyses indicated that Type A ER-
positive breast tumors are associated with significantly
better patient survival (following adjuvant treatment)
than Type B ER-positive tumors, in which the poorer
patient survival was comparable to that of a third
subset of ER-negative tumors that overexpress ErbB2
(HER2/neu).
Action item. Independent microarray and clustering
analyses are needed from a larger sample of patients
to confirm the existence of Type A and Type B ER-
positive breast tumor subsets with their significantly
different patient outcomes, and to verify that differ-
ences in responsiveness to endocrine adjuvant therapy
accounted for these outcome differences. Further im-
munohistochemical analysis of the Type A versus
B ER-positive tumors with probes not represented
on the microarray (e.g., PR) may confirm and fur-
ther characterize these microarray-determined breast
tumor subsets.
3. Progesterone receptor (PR) status has formerly
been shown to predict two subsets of ER-positive
metastatic breast cancer: ER-positive/PR-positive tu-
mors that have a response rate to endocrine therapy
nearly 2-to-3-fold higher than that of ER-positive/PR-
negative tumors. Using a well-validated PR assay
and looking at the longterm outcome of ER-positive
primary breast tumors treated with adjuvant endocrine
therapy (primarily tamoxifen), it now appears that pa-
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tients with ER-positive/PR-negative primary tumors
also have significantly worse relapse-free and over-
all survival compared to those with ER-positive/PR-
positive primaries. Furthermore, while increasing pa-
tient age is associated with increasing likelihood of an
ER-positive primary, the proportion of poorer-risk ER-
positive/PR-negative breast tumors also increases with
age.
Action item. Since the poor-risk predictive value
of ER-positive/PR-negative breast tumors has largely
been determined after endocrine therapy with the par-
tial ER antogonist, tamoxifen, the poor-risk predictive
value of ER-positive/PR-negative tumor status after
treatment with other endocrine therapies should also
be evaluated; in particular, tumor response rates and
patient survival for these two ER-positive tumor sub-
sets should be compared after ovarian ablation (sur-
gical, medical), aromatase inhibition, and treatment
with a pure estrogen antagonist (e.g., faslodex).
Mechanism of action of ERα and ERβ in relation
to SERMs and the development, progression and
prevention of breast cancer
Human mammary epithelial cells and many breast
carcinomas express one or both of the two estrogen
receptors, ERα and ERβ. Undoubtedly, the single most
important marker of estrogen sensitivity and response
to tamoxifen therapy in breast cancer is the presence
of ERα in tumor cells. ERα is also considered a signi-
ficant target for breast cancer prevention by selective
estrogen receptor modulators (SERMs) like tamoxifen
and raloxifene, as demonstrated by the NSABP P1
and MORE trials. Considerably less is known at this
point about the expression and function of ERβ in
normal breast epithelium and in breast cancer. Estro-
gens and SERMs regulate diverse cellular activities via
one or both of the two ER subtypes (ERα and ERβ)
in hormone responsive tissues and cancers. Liganded
ERs can interact with a complex mix of coactivators,
corepressors and other signaling molecules that differ
in expression and importance from tissue to tissue.
In addition, different SERMs may alter the affinity
and/or selectivity of one or both ERs for these coreg-
ulators, allowing for tissue selective responses. There
is also suggestive evidence that the two ER subtypes
may oppose each other in different cell contexts. It
is certainly true that ERα and ERβ can have different
actions in the same tissue and that they can interact
with each other, which may result in complex estro-
genic/antiestrogenic responses to a given ligand. Thus,
ERβ can stimulate AP1-activated genes in the pres-
ence of SERMs like tamoxifen, while inhibiting the
same genes in the presence of full estrogens like es-
tradiol and DES, whereas ERα appears to enhance
AP1-responsive genes in the presence of both agon-
ists and antagonists. Recently, partial insight into the
molecular basis of estrogen agonism and antagonism
has been revealed by the crystal structures of ERα and
ERβ ligand binding domains (LBDs) complexed with
several ligands, including estradiol (E2), diethylstil-
bestrol (DES), raloxifene (RAL), 4-hydroxytamoxifen
(OHT), the phytoestrogen genistein (GEN) and the
so-called complete antagonist ICI 182,780 (faslodex).
This information has helped define and predict some
of the properties and behaviors one might expect from
different SERMs. However, our knowledge of ER-
mediated responses to diverse natural and synthetic
SERMs is far from complete. Added to this com-
plexity is an increasing body of evidence to suggest
that rapid, nongenomic actions of SERM-ER com-
plexes may be an important and largely unappreci-
ated mechanism by which SERMs regulate prolifer-
ation, apoptosis and other cell-specific responses to
SERMs. Thus, the current challenges in this area
are:
1. Understanding the molecular mechanisms by
which SERMs elicit tissue-selective agonist or
antagonist responses via one or both ER subtypes.
2. Understanding the roles of ERα or ERβ expres-
sion and modification in breast cancer genesis and
progression to hormone independence.
Action items. Additional molecular and structural in-
formation is needed to improve our knowledge of how
the two ER subtypes (ERα and ERβ) mediate indi-
vidual and collective responses to SERMs, especially
in concert with multiple coactivators and corepressors.
More information is also needed about the expression
and possible roles of both ERs and their isoforms,
especially ERβ, in normal breast epithelium and in
progressive breast disease. Both correlative and mech-
anistic approaches are required to define the roles of
ERα and ERβ in these processes and to selectively
target each ER and/or associated signaling pathways,
such as over- or under-expressed coregulators (e.g.,
AIB1 or NCoR), for therapeutic or preventive inter-
vention. DNA array technology should be well suited
for identifying complex hormone signaling pathways
in normal and diseased tissues and for identifying
altered gene profiles in hormone responsive and un-
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responsive breast cancers as well as patient responses
to neoadjuvant therapy like tamoxifen.
Estrogens and other hormones as specific
explanations for recognized hormonal risk and
prognostic factors, and their underlying
mechanisms of action
Many conditions associated with elevated estrogen
and progestin levels are established breast cancer risk
factors. Less clear are the mechanisms through which
these hormones operate. For a number of conditions
associated with elevation in these hormones (hormone
replacement therapy (HRT), obesity, pregnancy, per-
haps moderate alcohol consumption), increased risk
appears almost instantaneously following exposure
and dissipates rapidly following cessation of exposure.
The protection associated with oophoretomy and use
of selective estrogen receptor modulators (SERMs)
appears equally as rapidly. These observations imply
an important role for these hormones acting relatively
late in carcinogenesis, perhaps involving tumor growth
promotion.
Even less clear are the mechanisms of action of
hormonal exposures associated with risk factors that
operate earlier in carcinogenesis (e.g., height, the
timing of menarche and of first full-term birth, geo-
graphic and ethnic differences, birth weight, being
the product of a toxemic pregnancy). Speculation on
mechanism has included hormonal influences on size
of stem cell populations, breast duct mass, mitogen-
esis, cellular differentiation, and DNA damage and
repair processes.
While most focus has been on the role of estrogen
and progestin in explaining breast cancer risk factors,
the full range of hormones involved is unknown.
There is increasing laboratory evidence for a role for
other hormones, many of which are also strongly as-
sociated with recognized breast cancer risk factors.
Recently, both laboratory and epidemiologic findings
have raised particular interest in androgens, glucocor-
ticoids, insulin and insulin-like growth factors (IGFs),
and prolactin.
Many of the conclusions with respect to carci-
nogenesis apply as well to issues of treatment and
prognosis. Obesity, ovarian function, pregnancy and
hormone-based therapies all influence the natural his-
tory and prognosis of breast cancer. While much of
the emphasis has rightfully been on the role of estro-
gen and progestin, the range of hormones potentially
involved is unknown, and likely to be broader. Ac-
cumulating clinical evidence of a potential prognostic
role for the IGFs, and recent laboratory findings im-
plicating glucocorticoid receptor activation in inhibit-
ing mammary epithelial cell apoptosis are particularly
provocative.
Action Items.
1. Interdiction of effective exposure to increased
levels of estrogen and progestin relatively late in
carcinogenesis can reduce breast cancer risk. Be-
havioral approaches to this include weight loss,
reduction of alcohol consumption and termination
of HRT, even at older ages. Use of SERMs are
also effective but development of new SERMs with
lower frequency of serious side effects will be re-
quired in order to make them more applicable to a
broader range of high-risk women.
2. Future opportunities for prevention and individual-
ized treatment based on hormonal influences will
require a better understanding of the range of hor-
mones involved and their underlying mechanisms
of action in breast tissue. Among the ways to
achieve this are interdisciplinary efforts to under-
stand hormonal risk and prognostic factors. Such
studies should include evaluation of a broad range
of hormones (estrogens, progestins, androgens, in-
sulin and IGFs, glucocorticoids, prolactin, and
others) and be focused not only on identifying
which hormones are involved when, but also on the
underlying mechanisms likely to be responsible for
their effects.
It is uncertain how much benefit is derived from
treatment with adjuvant chemotherapy in women
with receptor positive tumors who have also been
given an optimal adjuvant endocrine therapy
This questions has arisen, in part, from the results
of two large trials in which patients were randomized
to either four cycles of cyclophosphamide plus dox-
orubicin (CA) or the same regimen followed by four
cycles of paclitaxel. In both studies, a reduction in the
hazard of recurrence or death from adding paclitaxel
were seen only in those patients whose tumors were
estrogen and/or progesterone receptor negative. This
result was unexpected because prior adjuvant studies
have generally demonstrated that chemotherapy is ef-
fective in patients with receptor positive tumors, and
combinations of chemotherapy plus tamoxifen have
been shown to be better than tamoxifen alone. In over-
views or meta-analyses of trials in which paclitaxel
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was not used, the reduction in annual odds of recur-
rence or death from adjuvant chemotherapy is smaller
when the chemotherapy is given with tamoxifen than
when it is given alone. These differences do not reach
levels of conventional statistical significance, but the
duration of tamoxifen in the studies included in the
overviews varied from 1 to 5 years and not all patients
had receptor positive tumors. We now know that 5
years of tamoxifen is significantly better than shorter
durations. Since several large trials have demonstrated
that non-paclitaxel regimens plus 5 years of tamoxifen
are more effective than 5 years of tamoxifen alone
in postmenopausal patients with receptor positive tu-
mors, the differences in the duration of tamoxifen is
not, by itself, sufficient to explain the differences in
outcome between the adjuvant paclitaxel studies and
those included in the overviews. However, the vari-
able results from adding chemotherapy to tamoxifen
in patients with receptor positive tumors are sufficient
to generate a testable hypothesis. Adjuvant chemother-
apy may not improve disease-free and overall survival
in patients whose tumors are strongly receptor positive
and who have been given optimal adjuvant endocrine
therapy.
Action Item.
1. Adjuvant chemotherapy trials should stratify pa-
tients on the basis of receptor positivity. This will
help physicians and patients with receptor positive
tumors determine whether the added time free of
recurrence or the added survival, if any, is worth
the additional toxicity associated with chemother-
apy compared to using optimal endocrine therapy
alone.
2. The effects of chemotherapy should be correlated
with different levels of estrogen receptor posit-
ivity, the presence of both an estrogen and pro-
gesterone receptor, and newer markers of tumors
responsiveness to endocrine therapy.
The egf receptor family of growth factors and
ligands as targets for anticancer therapy
The egf receptor (efgr) family of growth factors and
ligands has emerged as one of the most attractive areas
for the development of anticancer therapy. There are
multiple bases for this assertion.
First, a wealth of information has suggested that
these gene products play pathophysiologic roles in
oncogenesis. Mutations in the transmembrane do-
main of the egfr are responsible for multiple chem-
ical carcinogen induced tumors in model systems.
Mutations resulting in truncated, spontaneously ac-
tivated forms of the egfr contribute to the pathogen-
esis of gliomas in humans and similar altered gene
products resulting from alternative spling contrib-
ute to breast and other solid tumors. Overexpression
due to gene amplification of HER2/neu [ErbB2] oc-
curs in varying proportions of many human tumors
including breast, ovary, bladder, gastric and lung
cancers.
Second, extensive prognostic studies suggest that
overexpession of family members is associated with
a worse prognosis in many human cancers including
breast, ovary, lung, gliblastoma and gastric carcino-
mas. Whilst not proving a pathogenetic role in these
tumors, work from animal models would strongly
support such a contention. Overexpression of the
egfr and ErbB2 in breast cancer are both associated
with a greater liklihood of hormone independence as
well.
Third, and most excitingly, at least two independ-
ent strategies aimed at altering signaling through these
receptor systems have shown encouraging efficacy in
humans with cancer. These studies place on a firm
foundation the notion that these receptors are involved
in disease pathogenesis. Antibodies directed against
the egfr are capable of inducing profound antican-
cer effects in squamous cell tumors of the head and
neck particularly when combined with either stand-
ard chemotherapy or irradiation. Similarly, antibodies
directed against ErbB2 have now been approved for
human use in breast cancer where their combination
with taxanes has been proven to both increase re-
sponse rate and prolong survival in metastatic disease.
This latter approach is now being explored in the
adjuvant setting. In addition to antibody approaches
several groups and pharmaceutical companies have
developed potent inhibitors of the intracellular kinase
domain of these receptors which are required for
their activity. Early clinical trials suggest signific-
ant grounds for encouragement. Thus it is clear that
the egfr family is critically involved in many human
cancers.
Hormone replacement therapy as a risk factor
Postmenopausal estrogen-progestin replacement ther-
apy increases breast cancer risk to a significantly
greater extent than does estrogen replacement therapy.
Postmenopausal estrogen replacement therapy (ERT)
at the dose usually administered in the U.S. increases
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breast cancer risk approximately 2% per year of use
(relative risk, RR, of 1.02 per year of use). Five
years of ERT use increases risk by approximately 5
times this amount (RR ∼ 1.10 per 5 years of ERT use),
and longer use increases the risk proportionately (e.g.,
RR ∼ 1.20 per 10 years of ERT use).
ERT is associated with much greater increased
relative risks for endometrial cancer (RR ∼ 2.0 per
5 years of ERT use). The endometrial cancer risks
were established in the mid 1970s, and, in response
to the greatly increased risks, progestins were ad-
ded to ERT (estrogen-progestin replacement therapy;
EPRT). The progestin is either added for 10–12 days
per month in a sequential fashion (sequential estrogen-
progestin replacement therapy; SEPRT), or estrogen
and a lower dose of progestin are always taken to-
gether (continuous-combined estrogen-progestin re-
placement therapy; CCEPRT).
Recent breast cancer case-control studies have
shown that EPRT use increases breast cancer risk to
a much greater extent than ERT use. These studies
suggest that the relative risk per year of EPRT use is
approximately three times that associated with ERT
use, that is RR ∼ 1.06 per year of EPRT use. Five
years of EPRT use increases risk by approximately
five times this amount (RR ∼ 1.30 per 5 years of EPRT
use), and longer use increases the risk proportionately
(e.g., RR ∼ 1.60 per 10 years of ERT use). Evid-
ence that these effects are directly due to the EPRT
use comes from the randomized trial (the PEPI trial)
that showed substantial increases in mammographic
densities in women taking EPRT, much greater in-
creases than were seen in the ERT arm of the trial.
Further evidence comes from the finding of greatly
increased breast cell proliferation in women using
EPRT.
Progestins clearly need to be given to protect the
endometrium from the carcinogenic effects of unop-
posed ERT. They need to be delivered to the endo-
metrium in a manner that will have a minimal ef-
fect on the breast. There is good evidence that this
can be accomplished by using a ‘direct’ endometrial
route of administration with use of an intra-uterine
device (IUD) containing progesterone (Progestasert),
that was designed as an intra-uterine contraceptive
device (IUCD) for premenopausal women. Use of this
device is associated with a very low serum proges-
terone concentration of < 1.5 nmol/l (follicular phase
of the menstrual cycle). The recently FDA-approved
levonorgestrel containing IUCD (Mirena) will prob-
ably also provide endometrial protection with very
little effect on the breast, although this would need
to be demonstrated. Alternatively, it may be possible
to administer micronized progesterone by an intra-
vaginal tablet at a dose that will provide adequate
endometrial progestin levels with low blood levels so
that the effects of the progesterone on the breast should
be small. If these routes of administration are unac-
ceptable to a woman then giving progestins for 10
days every 3 to 4 months should provide satisfactory
protection of the endometrium with much less effect
on the breast than current forms of EPRT. Two clin-
ical trials of 10 mg per day of medroxyprogesterone
acetate (MPA) given for 14 days every 3 months have
been published, in which the dose of estrogen was con-
jugated estrogens at 0.625 mg/day. These two studies
suggest that this approach may be satisfactory in that
the extent of associated endometrial hyperplasia was
minimal. A further trial did not show satisfactory con-
trol of hyperplasia, but in this trial a much higher dose
of estrogen was given.
It is not clear how the relative risks for breast
cancer associated with EPRT use in the form of con-
jugated estrogens as measured in the two U.S. studies
apply to other forms of EPRT that use a transdermal
(patch) delivery system or use different progestins in
different schedules.
Action Items.
1. Encourage the development of an IUD device spe-
cifically designed for postmenopausal women. The
device needs to deliver just sufficient progestin
to the endometrium to block the action of re-
placement doses of estrogen. The device needs
to be designed to only need replacing very in-
frequently.
2. Encourage studies of the vaginal route of admin-
istration of progesterone with ERT, in order to
find the minimum dose and duration of therapy
adequate to protect the endometrium. Since the
dose-duration response relationship of progestin
with ERT on the breast is so poorly understood, it
is necessary with both of the above Items to incor-
porate studies of their actions on the breast (e.g.,
using mammographic density or other biomarkers
of action).
3. Encourage the FDA to make measurement of the
effects on the breast part of the licensing of any
new forms of EPRT. Encourage the FDA to require
of manufacturers of all forms of EPRT currently
licensed in the U.S. to make measurements of their
effects on the breast.
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Breast cancer prevention via a hormonal or
dietary mechanism
The role of hormones in the initiation of breast can-
cer remains unclear. However, reduction in estrogen
levels by bilateral ovariectomy or inhibition of estro-
gen receptor action by tamoxifen significantly reduces
breast cancer risk. These effects are present for the
risk of developing breast cancer in either pre- or post-
menopausal women as well as those who are at high
familial risk (i.e., BRCA1/BRCA2 mutation carriers).
Surprisingly, no apparent association has been found
between increased estrogenicity during reproductive
years and premenopausal breast cancer risk. Further,
dietary components or life-style factors associated
with altered estrogenicity, such as dietary intake of
fat or phytoestrogens (esp. soy) or physical activ-
ity, have not been clearly linked to breast cancer
risk. High estrogen levels characterizing pregnancy
actually reduce breast cancer risk. Additionally, in-
creased levels of adipose tissue -derived estrogens dur-
ing childhood and premenopausal years are associated
with reduced risk of developing breast cancer, while
postmenopausal obesity increases the risk. Accumu-
lating evidence indicates that the timing of hormone
and dietary exposures might play as an important role
in affecting breast cancer risk as life-time exposures.
For example, both human and animal data suggest
that high in utero estrogenicity, including that induced
by dietary means, may pre-initiate breast cancer. This
could result from changes in the morphological devel-
opment of the breast and altered expression of genes
that play a critical role in estrogen’s signal trans-
duction pathways. Virtually nothing is known about
estrogen exposures during childhood and breast cancer
risk, or the ability of childhood diet to alter the risk.
Action items.
1. Explore associations between in utero and child-
hood estrogenic exposures and breast cancer risk.
Include women who are at high familial risk,
such as BRCA1/BRCA2 mutation carriers to these
studies.
2. Identify modifiable factors that can alter estrogen-
icity in utero and during childhood. These factors
are likely to be linked to diet and physical activity.
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